Infanrix-Ipv

Pertussis Toxoid Adsorbed On Aluminium Hydroxide, Pertussis Pertactin Adsorbed On Aluminium Hydroxide, the active ingredient in Infanrix-Ipv, is a vaccine presented as an injectable solution for intramuscular use. It is used to prevent pertussis (whooping cough) in infants and children as part of routine immunisation programmes approved in the European Union.

GNH USA supplies Infanrix-Ipv as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Infanrix-Ipv is a pertussis vaccine that stimulates immunity against the bacterium responsible for whooping cough. - Prevention of pertussis: provides active immunisation against Bordetella pertussis in infants and young children. - Primary immunisation schedule: administered as part of the first series of childhood vaccines to establish early protection. - Booster dose: given later in childhood to maintain protective antibody levels.

Like all vaccines, Infanrix-Ipv may be associated with local and systemic reactions.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness at injection site: localized erythema that resolves within a few days. - Fever: low‑grade temperature rise occurring within 24‑48 hours. - Irritability: temporary fussiness or crying in infants.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Seizures: rare febrile convulsions following vaccination. - Persistent high fever: prolonged temperature above 40°C that may need evaluation.

Before administering Infanrix-Ipv, certain safety considerations should be observed. - Screen for severe allergy: assess history of hypersensitivity to vaccine components. - Delay vaccination: postpone if the child has a moderate or severe acute illness. - Observe after injection: monitor for at least 15 minutes for immediate reactions. - Contraindicated in known anaphylaxis to pertussis antigens. - Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Infanrix-Ipv has limited pharmacological interactions, but certain co‑administrations require attention.

Major Interactions (Avoid): - Concurrent administration with other pertussis‑containing vaccines: may increase reactogenicity. - Use with immunoglobulin products: can diminish vaccine‑induced immunity.

Moderate Interactions (Monitor Closely): - Immunosuppressive therapy: may reduce the immune response to the vaccine. - Antipyretics (e.g., acetaminophen): may mask fever, a common post‑vaccination sign. - Blood products given shortly before or after vaccination: could interfere with antibody development.